Drug Trial Radar · NCT05966480
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
408
Actual
Start
Jun 26, 2023
Primary completion
Jun 23, 2026
Study completion Sep 1, 2027
Sponsor
- Lead sponsor
- Alumis IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.
Conditions
- SLE
Interventions
EnvudeucitinibDrug
Oral tablet
PlaceboDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the effect on disease activity measured by the proportion of patients achieving British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response at Week 48 between doses of ESK-001 and placeboTime frame: Week 48
Locations
169 sites in 21 countries. Site status is shown where the registry gives one.
Investigator Site #1046
Anniston, Alabama
Investigator Site #1104
La Jolla, California
Investigator Site #1050
Los Alamitos, California
Investigator Site #1168
Mission Hills, California
Investigator Site #1174
Napa, California
Investigator Site #1061
Upland, California
Investigator Site #1048
Aventura, Florida
Investigator Site #1063
Avon Park, Florida
Investigator Site #1176
Bradenton, Florida
Investigator Site #1045
Clearwater, Florida
Investigator Site #1055
Coral Gables, Florida
Investigator Site #1097
Coral Springs, Florida
Investigator Site #1091
Daytona Beach, Florida
Investigator Site #1051
DeBary, Florida
Investigator Site #1087
Hollywood, Florida
Investigator Site #1135
Kissimmee, Florida
Investigator Site #1060
Miami, Florida
Investigator Site #1093
Miami, Florida
Investigator Site #1057
Miami, Florida
Investigator Site #1067
Miami Lakes, Florida
Investigator Site #1090
Plantation, Florida
Investigator Site #1089
Tampa, Florida
Investigator Site #1170
Atlanta, Georgia
Investigator Site #1052
College Park, Georgia
Investigator Site #1204
Chesterfield, Missouri
Investigator site #1209
Las Vegas, Nevada
Investigator Site #1189
Sparta, New Jersey
Investigator Site #1101
Albuquerque, New Mexico
Investigator Site #1058
Brooklyn, New York
Investigator Site #1088
New York, New York
Investigator Site #1175
Queens, New York
Investigator Site #1095
Charlotte, North Carolina
Investigator Site #1056
Charlotte, North Carolina
Investigator Site #1173
Charlotte, North Carolina
Investigator Site #1171
Philadelphia, Pennsylvania
Investigator Site #1062
Pittsburgh, Pennsylvania
Investigator Site #1044
Memphis, Tennessee
Investigator Site #1195
Carrollton, Texas
Investigator Site #1049
Colleyville, Texas
Investigator Site #1071
Fort Worth, Texas
Showing 40 of 169 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.